IonOpticks responds to growing global market needs for proteomics tools by partnering with Nordic private equity firm MELBOURNE, Australia and STOCKHOLM , Sept. 9, 2024 /PRNewswire/ -- IonOpticks , a leading global producer of high-performance chromatography columns, announces its partnership with Adelis Equity Partners ("Adelis"). The Nordic private equity firm is renowned for partnering with and accelerating the growth of companies in their focus sectors including healthcare and life sciences.
The investment from Adelis will augment IonOpticks' global presence and drive innovation as the company expands closer to key markets and consolidates its leading position in the exciting and rapidly growing field of proteomics and adjacent applications. The strategic partnership will enable IonOpticks to scale its operations globally, enhancing product development and better positioning the company to serve its growing customer base. Being closer to its customers and collaborators while also ensuring compatibility across major LC-MS platforms is a key priority, allowing researchers worldwide to benefit from IonOpticks' class-leading chromatography.
Adelis' extensive experience, industrial advisor network and resources will support IonOpticks in maintaining its position as the provider of the best solutions for LC-MS proteomics research. IonOpticks also strengthens its board with the appointment of several industry heavyweights, including Dr. Peter Wrighton-Smith as Chairman.
With an .